Verastem (VSTM) Receives Media Sentiment Score of 0.06
News headlines about Verastem (NASDAQ:VSTM) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Verastem earned a media sentiment score of 0.06 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 46.810994170877 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the news stories that may have effected Accern’s rankings:
- Head to Head Contrast: Verastem (VSTM) & Obseva (OBSV) (americanbankingnews.com)
- Verastem Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (finance.yahoo.com)
- Verastem, Inc. (NASDAQ:VSTM) – What is The Actual Stock’s Value – Complete Picture in Focus – Nasdaq Journal (nasdaqjournal.com)
- Verastem (VSTM) Upgraded to “Hold” at Zacks Investment Research (americanbankingnews.com)
- Simple Moving Averages to Consider – Verastem, Inc. (NASDAQ … – The Investor Guide (wallstreetnews24.com)
A number of equities research analysts have weighed in on VSTM shares. Cann reaffirmed a “buy” rating and issued a $15.00 target price (up previously from $6.00) on shares of Verastem in a report on Sunday, December 10th. Cantor Fitzgerald set a $17.00 target price on Verastem and gave the company a “buy” rating in a report on Sunday, December 10th. Roth Capital started coverage on Verastem in a report on Friday, December 1st. They issued a “buy” rating and a $12.00 target price on the stock. HC Wainwright set a $10.00 target price on Verastem and gave the company a “buy” rating in a report on Wednesday, December 13th. Finally, Zacks Investment Research raised Verastem from a “sell” rating to a “hold” rating in a report on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company. Verastem has a consensus rating of “Buy” and a consensus target price of $9.53.
In other news, Director Timothy J. Barberich acquired 60,538 shares of the business’s stock in a transaction that occurred on Tuesday, December 5th. The shares were bought at an average price of $3.95 per share, with a total value of $239,125.10. Following the acquisition, the director now directly owns 130,000 shares in the company, valued at approximately $513,500. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 6.51% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Verastem (VSTM) Receives Media Sentiment Score of 0.06” was first posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.watchlistnews.com/verastem-vstm-receives-media-sentiment-score-of-0-06/1909654.html.
Verastem Company Profile
Verastem, Inc is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584.
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.